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Abstract
 
Dendritic cell (DC) maturation is an innate response that leads to adaptive immunity to coad-
ministered proteins. To begin to identify underlying mechanisms in intact lymphoid tissues, we
studied 
 
 
 
-galactosylceramide. This glycolipid activates innate V
 
 
 
14
 
 
 
 natural killer T cell
(NKT) lymphocytes, which drive DC maturation and T cell responses to ovalbumin antigen.
Hours after giving glycolipid i.v., tumor necrosis factor (TNF)–
 
 
 
 and interferon (IFN)-
 
 
 
 were
released primarily by DCs. These cytokines induced rapid surface remodeling of DCs, including
increased CD80/86 costimulatory molecules. Surprisingly, DCs from CD40
 
   
 
 and CD40L
 
   
 
mice did not elicit CD4
 
 
 
 and CD8
 
 
 
 T cell immunity, even though the DCs exhibited pre-
sented ovalbumin on major histocompatibility complex class I and II products and expressed
high levels of CD80/86. Likewise, an injection of TNF-
 
 
 
 up-regulated CD80/86 on DCs, but
CD40 was required for immunity. CD40 was needed for DC interleukin (IL)-12 production,
but IL-12p40
 
   
 
 mice generated normal ovalbumin-specific responses. Therefore, the link
between innate and adaptive immunity via splenic DCs and innate NKT cells has several com-
ponents under distinct controls: antigen presentation in the steady state, increases in costimulatory
molecules dependent on inflammatory cytokines, and a distinct CD40/CD40L signal that
functions together with antigen presentation (“signal one”) and costimulation (“signal two”) to
generate functioning CD4
 
 
 
 T helper cell 1 and CD8
 
 
 
 cytolytic T lymphocytes.
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Introduction
 
DCs in lymphoid tissues can initiate antigen-specific adap-
tive responses: both peripheral tolerance and immunity (for
reviews see references 1–3). The administration of a stimulus
for maturation switches DC function from tolerance to
immunity, including the development of CD4
 
 
 
 T cells of
the Th1 type, and active cytolytic CD8
 
 
 
 T cells. Although
much of the early work on DC maturation was performed
in culture, the process has begun to be studied in vivo, par-
ticularly in lymphoid organs (4, 5), which are the tissues
involved in the generation of tolerance and immunity. In
the steady state, in the absence of overt inflammatory and
infectious stimuli, many DCs in lymphoid organs are defined
as immature, able to endocytose (6–8), and process antigens
to form peptide complexes with MHC class I and II prod-
ucts (8–11), but unable to initiate the differentiation of effector
T cells and memory. Instead, DCs in the steady state, or
subsets of DCs, elicit different forms of peripheral toler-
ance, such as deletion (9, 10), anergy (12), and the expan-
sion of regulatory T cells (13). If the antigen-capturing
DCs are exposed to a stimulus that leads to their maturation
in vivo (5, 9, 10, 14–17), strong T cell immunity develops,
especially CD4
 
 
 
 and CD8
 
 
 
 effector T cells capable of
IFN-
 
 
 
 production and cytolysis. Thus, the avoidance of
tolerance and the initiation of immunity are major correlates
of DC maturation; it is important to identify underlying
mechanisms particularly in the intact animal.
To begin to identify in vivo mechanisms that drive DC
maturation and link innate with adaptive immunity, we
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have dissected the DC response in lymphoid tissues to the
synthetic glycolipid, 
 
 
 
-galactosylceramide (
 
 
 
-GalCer). This
glycolipid is presented by CD1d molecules to the conserved
V
 
 
 
14 T cell receptor on innate NKT cells (18). 
 
 
 
-GalCer,
in an NKT cell–dependent fashion, acts as an adjuvant for T
cell immunity (19) and as an inducer of maturation in
splenic DCs (15, 16). The 
 
 
 
-GalCer/NKT system is attrac-
tive to study the role of different components of DC matu-
ration in vivo. Several cardinal features of maturation are en-
gaged within 4–8 h of a single i.v. dose of 
 
 
 
-GalCer. There
is a marked up-regulation of CD40, 80, and 86 costimula-
tory and MHC class II antigen-presenting molecules, identi-
cal to that observed with toll-like receptor stimuli in vivo,
such as lipopolysaccharide (4) and CpG oligonucleotides (5).
The DCs also start to produce large amounts of cytokines
such as IFN-
 
 
 
 and IL-12 (15). Importantly, if a small
amount of cell-associated antigen is administered together
with 
 
 
 
-GalCer, the DCs initiate combined CD4
 
 
 
 and
CD8
 
 
 
 T cell immunity to that protein. Specifically, a single
dose of 
 
 
 
1 
 
 
 
g of OVA within dying cells leads to strong
immunity, including protection of OVA-transduced tumors
(15); this protection persists for at least 2 mo (unpublished
data). To prove that maturing DCs are directly responsible
for the induction of immunity, DCs can be removed from
mice 4–8 h after giving 
 
 
 
-GalCer and antigen. When trans-
ferred to naive animals, these DCs initiate immunity with-
out further antigen, 
 
 
 
-GalCer, or NKT cells (15). An analo-
gous conclusion on the importance of maturing DCs was
reached by Shah et al., who adoptively transferred immunity
with DCs responding to CpG oligonucleotides (20).
Therefore, the 
 
 
 
-GalCer system provides an opportunity
to identify mechanisms whereby maturing DCs convert a
single low dose of antigen into strong and prolonged CD4
 
 
 
and CD8
 
 
 
 T cell immunity. Interestingly, NKT lympho-
cytes rather than microbial stimuli forge the link between
innate and adaptive immunity. We will show that different
elements in the immunization process are under distinct
controls, and that a particularly critical one entails CD40 li-
gation. It is well known that CD40 acts as a DC maturation
stimulus in culture, increasing the expression of CD80 and
CD86 (21, 22), enhancing antigen presentation (23, 24),
and inducing IL-12 production (25, 26). Also, CD40 is re-
quired for DC function in vivo, particularly for CD8
 
 
 
 T
cell responses (27–29). Mechanistically, it has been assumed
that CD40 ligation triggers DCs to express the two pre-
sumed requirements for immunity, antigen presentation or
“signal one” and up-regulation of membrane and cytokine
costimulators or “signal two.” Here, we find that cyto-
kines, independently of CD40 ligation, are responsible for
the maturation of DCs when this is assessed by increased
expression of CD80/86 in vivo. Nonetheless, CD40 and
CD40L are required by DCs to induce both CD4
 
 
 
 and
CD8
 
 
 
 T cell immunity even when the DCs are expressing
high levels of MHC peptide and costimulatory molecules.
At least in the 
 
 
 
-GalCer/NKT system, it appears that more
is required for DCs to initiate immunity than the combina-
tion of signals one and two.
 
Materials and Methods
 
Mice. 
 
Pathogen-free C57BL/6 (B6), IFN-
 
 
 
   
 
, IFN-
 
 
 
R
 
   
 
,
TNF-
 
 
 
   
 
, and TAP
 
   
 
 female mice at 6–7 wk were purchased
from The Jackson Laboratory. Mice deleted of J
 
 
 
281 (J
 
 
 
18)
genes were provided by M. Taniguchi (Institute of Physical and
Chemical Research, Yokohama, Japan). Mice were maintained
under specific pathogen-free conditions and studied in compli-
ance with institutional guidelines.
 
Reagents. 
 
 
 
-GalCer (2S,3S,4R-1-
 
O
 
(
 
 
 
-galactopyranosyl)-2(
 
N
 
-hex-
acosanoylamino)-1,3,4-octadecanetriol and vehicle were provided
by the Pharmaceutical Research Laboratory and diluted in PBS.
LPS-free OVA was obtained from the Seikagaku Corp. The fol-
lowing mAbs were obtained from BD Biosciences: FITC-conju-
gated 
 
 
 
-CD4, 
 
 
 
-CD8
 
 
 
 or PE-conjugated 
 
 
 
-CD8
 
 
 
, allophycocya-
nin-conjugated 
 
 
 
-CD11c, biotinylated isotype control, 
 
 
 
-CD40,
CD80, and CD86. Biotinylated mAbs were detected with streptavi-
din-allophycocyanin. IFN-
 
 
 
 mAb (R4-6A2) was purified from hy-
bridoma (American Type Culture Collection) supernatants.
 
Flow Cytometry for DC Surface Markers. 
 
Cells were preincu-
bated with 2.4G2 culture medium to block Fc
 
 
 
R, washed, incu-
bated with mAb conjugates for 30 min, washed, and analyzed on
a FACSCalibur™ flow cytometer (Becton Dickinson).
 
DC Preparation from Spleen. 
 
Using methods described previ-
ously (30), splenocytes were released by teasing and treatment
with collagenase D (Roche Diagnostics Corp.). For flow cytom-
etry, DC-enriched cells were obtained as a low-density fraction
on BSA columns (30). In functional assays, we separated CD11c
 
 
 
fractions with 
 
 
 
-CD11c–coated magnetic beads immediately af-
ter collagenase treatment, followed by labeling with 
 
 
 
-CD11b–
PE and PE-magnetic beads (MACS).
 
Cytokine Production by DCs. 
 
CD11c
 
 
 
 DC enriched, CD11c
 
 
 
CD11b
 
 
 
 monocyte-enriched, and CD11c
 
 
 
CD11b
 
 
 
 lymphocytes,
isolated as aforementioned with magnetic beads 2 h after mice
were given i.v. 
 
 
 
-GalCer or vehicle, were cultured at 2 
 
 
 
 10
 
5
 
cells/well for 24 h in 96-well plates. The supernatants were assayed
with the following ELISA kits for cytokines: IFN-
 
 
 
 and IL-12p40
(Opti EIA; BD Biosciences); TNF-
 
 
 
 and IL-12p70 (Quantikine;
R&D Systems); and IFN-
 
 
 
 (PBL Biomedical Labs).
 
Antigen Uptake and Presentation In Vivo. 
 
To measure splenic
DC presentation of cell-associated antigens to T cells, we used as-
says described previously (7, 8) in which mice were injected with
2 
 
 
 
 10
 
7
 
 OVA-pulsed and osmotically shocked, syngeneic TAP
 
   
 
splenocytes (7). Osmotic shock causes cells to die, and these cells
are taken up by CD8
 
 
 
 splenic DCs. To monitor OVA presenta-
tion, mice were adoptively transferred with carboxyfluorescein
succinimidyl ester (CFSE)–labeled, CD8
 
 
 
 (OT-I) and CD4
 
 
 
(OT-II) OVA-specific TCR transgenic T cells. 3 d later, single
cell suspensions of spleen and lymph nodes were taken to moni-
tor T cell proliferation by dilution of CFSE, and T cell expansion
was expressed as the number of transgenic T cells in the spleen.
OT-I T cells were marked with CD45.1 and OT-II T cells were
marked by expression of V
 
 
 
5.1/5.2 and V
 
 
 
2.
 
Initiation (Priming) of T Cell Immunity. 
 
7 d after cell-associ-
ated OVA injection as aforementioned, recipient spleen cells
were tested for CD4
 
 
 
 and CD8
 
 
 
 T cell priming. 5 
 
 
 
 10
 
6
 
 cells
were cultured 6 h in 24-well plates 
 
 
 
1 
 
 
 
M OVA
 
257-264
 
 peptide
(for CD8
 
 
 
 T cells) or 2 
 
 
 
M OVA
 
323-339
 
 peptide (for CD4
 
 
 
 T
cells) with brefeldin A (BD Biosciences) to accumulate IFN-
 
 
 
 in-
tracellularly. Cells were incubated for 15 min at 4
 
 
 
C with 2.4G2
 
 
 
-Fc
 
 
 
R mAb to block nonspecific staining and with FITC
 
 
 
-CD4 or CD8 for 20 min at room temperature. After Cytofix/
Cytoperm Plus™ permeabilization (BD Biosciences), we stained 
Fujii et al.
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cells with PE-conjugated 
 
 
 
–IFN-
 
 
 
 (XMG1.2) mAb for 15 min
at room temperature and analyzed them with a FACSCalibur™
and CELLQuest™ (BD Biosciences) or FlowJo (Tree Star) soft-
ware. To monitor proliferation by immunized T cells, spleno-
cytes were labeled with 1 
 
 
 
M CFSE for 10 min at 37
 
 
 
C on day 7
and challenged for 3 d in vitro with 500 
 
 
 
g/ml OVA protein to
assess successive halving of CFSE/cell. Cytolytic activity of
CD8
 
 
 
 T cells in vivo was tested with a 1:1 mix of spleen cells, la-
beled CSFE
 
high
 
, and pulsed with OVA
 
257-264
 
; unpulsed cells were
labeled CFSE
 
low
 
. After washing, the cells were coinjected i.v. to
immunized B6 mice. 16 h later, we assessed a selective loss of
peptide-positive CFSE
 
high
 
 cells in spleen by FACS
 
®
 
.
DC Stimulation of the Mixed Leukocyte Reaction (MLR).
Spleen CD11c  DCs were isolated 8 h after administration of
 -GalCer or vehicle. Graded numbers of C57BL/6 DCs were irra-
diated, added to 2   105 allogeneic BALB/c or syngeneic (C57BL/6)
T cells, and isolated using T cell enrichment columns (R&D Sys-
tems) in 96-well flat-bottom plates for 88 h. During the final 16 h,
[3H]thymidine (1  Ci/well) was added. In some experiments, DCs
were fixed with 0.75% paraformaldehyde (Electron Microscopy
Science) for 30 min on ice before coculture with T cells.
Online Supplemental Material.  Six figures comprise this pa-
per’s online supplemental material. In Fig. S1, cytokine produc-
tion by splenic DCs after i.v.  -GalCer is shown. Fig. S2 depicts
the weak contribution of individual inflammatory cytokines in
the  -GalCer–induced remodeling of the DC surface. Fig. S3
shows the role of CD40L in the response to  -GalCer. In Fig.
S4, the critical role of a bone marrow–derived cell in presentation
of OVA associated with injected TAP    splenocytes is indicated.
Fig. S5 shows that IL-12p40 is not required to induce OVA-spe-
cific immunity by DCs maturing to  -GalCer. Fig. S6 contains a
summary diagram of the observed responses to a single i.v. dose
of  -GalCer. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20040317/DC1.
Results
Cytokine Production by DCs after i.v. Injection of  -GalCer.
To account for the rapid maturation of most DCs in the
spleens of mice given a single dose of  -GalCer, we assessed
the production of inflammatory cytokines because these
Figure 1. Cytokine production by splenic DCs in response to i.v.  -GalCer (A) Serum IFN-  and TNF-  levels 1, 2, and 4 h after mice received
2  g  -GalCer i.v.; no cytokines were detected in mice given vehicle only. (B) Production of cytokines by the indicated subsets (x axis) of splenocytes
isolated 2 h after vehicle or  -GalCer i.v., which is before the time that NK cells are activated. (C) FACS® for intracellular cytokines produced by splenic
CD11c  DCs taken from mice 2 h after injection of vehicle or  -GalCer and cultured for 4 h in brefeldin A; numbers are the percentage of CD8  and
CD8  CD11c  cells producing cytokines. (D and E) Maturation of splenic DCs, as assessed by CD86 expression, after blockade of both TNF-  and
IFN- . Vehicle or  -GalCer was given to wild-type or TNF-     mice treated with  -IFN-  antibody or control Ig (300  g/mouse) 3 h before injec-
tion of  -GalCer. Mean values for CD86 expression are shown for three experiments in four groups of mice. All results represent the mean of three or
more independent experiments (A, B, and D) or are representative (C and E).Distinct Controls for Dendritic Cell Maturation In Vivo 1610
drive DC differentiation (31–33). Both TNF-  and IFN- 
were detected in the serum 2–4 h after  -GalCer, but not in
mice given vehicle control (Fig. 1 A). To look for the cellu-
lar sources of cytokines, we prepared different cell popula-
tions 2, 8, and 24 h after i.v.  -GalCer and cultured the cells
without known stimuli for 24 h (in an earlier analysis, we
cultured the DCs with anti-CD40 for 72 h; reference 15).
IFN- , TNF- , IL-12p40, and IL-12p70 were each re-
leased in substantial amounts (ELISA assay), but only by en-
riched CD11c  DCs and not by enriched CD11b  CD11c 
macrophages and CD11b  CD11c  lymphocytes (Fig. 1 B).
We did not see a contribution of NKT cells in our assays be-
cause IL-4 was not detected in four out of four experiments.
Also, it is known that IFN- –producing NKT cells are evi-
dent at 2 h, but not 5 h, after  -GalCer (34). DC cytokine
production was also evident by intracellular cytokine
staining, permitting analyses of the contribution of CD3 
CD11c  DC subsets (Fig. 1 C). Interestingly, CD8   DCs
were the principal source of IFN-  and CD8   DCs for IL-
12p40 as in other studies (35), whereas both subsets made
TNF-  (Fig. 1 C). Cytokine production by FACS® was in-
creased if the DCs were assayed after longer culture periods
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20040317/DC1). IFN- , which can mature DCs, was
not detectably made by splenic CD8   or CD8  CD11c 
DCs (unpublished data). Also, when plasmacytoid DCs were
sorted at 2, 4, and 6 h after  -GalCer administration, we de-
tected no IFN-  and lower IL-12p70 and p40 ( 100 pg/
ml) in the supernatants. Thus, nonplasmacytoid DC subsets
act in concert to produce inflammatory cytokines and seem
to be their major source early after i.v.  -GalCer.
Cytokines Drive Increased Costimulatory Molecules on DCs
Maturing in Response to  -GalCer.  To determine the con-
sequences of TNF-  and IFN-  on DC maturation, we an-
alyzed the DC surface from TNF-    , IFN-    , and
IFN-  R    mice 4–8 h after  -GalCer. CD40, CD80, and
CD86 increased in the individual knockout mice much like
wild type, although there was slightly less up-regulation of
CD86 in TNF-     knockouts (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20040317/DC1). In
contrast, when we blocked both cytokines by injecting a
neutralizing  -IFN-  antibody (300  g/mouse) into TNF-
     mice, DC surface maturation was almost completely
abrogated (Fig. 1, D and E). Because B cells up-regulate
their surface markers in  -GalCer–treated mice (15, 36), we
tested if B cells contributed to DC maturation. However,
DCs from B cell–deficient JH
    mice responded compara-
bly to wild-type  -GalCer (unpublished data). Thus, TNF- 
and IFN-  are largely responsible for the changes in the DC
surface induced by  -GalCer.
The Response of Splenic DCs to Cytokine Administration In
Vivo.  To further assess the role of cytokines, we gave mice
TNF-  and IFN-  i.v. and examined the DCs 4–8 h later.
At sufficiently high doses, we observed an up-regulation of
costimulatory molecules, but the increases were smaller than
induced by  -GalCer, especially on the CD8  DC subset
(Fig. 2 A, left). TNF-  was primarily active because IFN- 
only had a modest effect and only on CD8  DCs (Fig. 2 A,
right). To test if the cytokine-stimulated DCs were immuno-
genic, we administered OVA as a protein antigen. Instead of
free OVA, where i.v. milligram doses are required for cap-
ture by splenic DCs, we used OVA associated with osmoti-
cally shocked splenocytes because submicrogram amounts of
cell-associated OVA are presented by splenic DCs (7, 8). The
injected splenocytes were always from TAP    mice, so that
the recipient DCs, which capture the injected cells within
30–60 min, were responsible for OVA presentation on
MHC class I (7, 8). 7 d later, spleen cells were cultured for
6 h without or with MHC class I and II binding peptides,
OVA 257-264, or OVA 323-339 in the presence of brefeldin A to
Figure 2. Function of DCs in
response to IFN-  and TNF- .
(A) Up-regulation of CD86 ex-
pression on splenic DC subsets 4 h
after administration of a single
low (20 ng IFN-  and 2 ng
TNF- /mouse), medium (200 ng
IFN-  and 20 ng TNF- ), or
high (2  g IFN-  and 200 ng
TNF- ) dose of TNF-  (left) or
a combination of high dose
TNF-  and IFN-  (right). (B)
Induction of some CD8  T cell
immunity when OVA-loaded
TAP    splenocytes were given
to mice followed 2 h later by
TNF-  (inset). Immunity was
monitored at 7 d by formation of
IFN- –secreting, OVA-specific
CD8  T cells.Fujii et al. 1611
quantify newly formed, IFN- –producing CD8  and CD4 
“effector” T cells by intracellular cytokine staining.
We found a lack of OVA-specific immunity in mice given
TNF- , IFN- , or both cytokines together with OVA-
loaded splenocytes (not depicted), in spite of the DC up-reg-
ulation of CD80/86 (Fig. 2 A). We were concerned that the
TNF-  stimulus may have diminished DC uptake and/or
processing of OVA, so we did the experiment another way,
giving the OVA 2 h before the TNF- . At that point, some
T cell immunity developed. At 1 wk,  0.2% of the CD8  T
cells could secrete IFN-  (Fig. 2 B, inset). However, if
we gave OVA-loaded splenocytes followed by TNF-  to
CD40    mice, a T cell response did not develop (Fig. 2 B),
even though CD80/86 costimulatory molecules were ele-
vated comparably to wild-type mice. These data indicated
that CD80/86 up-regulation by cytokines did not lead to im-
munity per se; a CD40-dependent step was needed.
CD40 on Maturing DCs, Activated by CD40L, Is Critical
for Immunogenicity Initiated by  -GalCer and NKT Cells.
We returned to the basic  -GalCer model and assessed the
effects of CD40 ablation on immunogenicity. It is known
that activation of NKT cells is intact in CD40    mice given
 -GalCer, using CD1d/ -GalCer tetramers to identify
NKT cells producing IFN-  and IL-4 (37). However, we
noted a major requirement of CD40 for CD8  and CD4  T
cell immunity because CD40    mice failed to generate re-
sponses to the coadministered OVA (Fig. 3 A). Mean values
of three such tests are shown in Fig. 3 B. To establish that
CD40 was operating at the level of the DCs, we used CD11c
selection to isolate these cells from immunized wild-type and
CD40    mice and transferred the DCs into naive mice that
were not given additional OVA or  -GalCer. CD11c  DCs
from  -GalCer–treated mice could initiate immunity when
transferred to naive mice as reported previously (15), but
DCs from CD40    mice were inactive (Fig. 3 C). This im-
plied that CD40L was essential for full DC maturation. In
fact, we found a 90% drop in the response to OVA plus
 -GalCer in CD40L    mice (Fig. S3 A, available at http://
www.jem.org/cgi/content/full/jem.20040317/DC1).
We confirmed the data (38) that 2 h after administration
of  -GalCer, CD40L increases on some NKT cells (gated
as CD3  NKT1.1  lymphocytes), and that this increased
CD40L occurred in mice lacking CD40 or subject to cyto-
kine blockade (Fig. S3 B). To test if CD40L on OVA-acti-
vated CD4  T cells might play a role in CD8  T cell prim-
ing, we used CD4    mice. When wild-type mice were
given cell-associated OVA and  -GalCer, and 4 h later,
DCs from these mice were obtained and transferred to na-
ive CD4    mice (thus lacking a CD4  T cell source of
CD40L), we observed OVA-specific CD8  T cell priming
1 wk later. These results suggest that an early CD40L–
CD40 interaction, presumably from NKT cells interacting
with DCs presenting glycolipids, critically allows immunity
to be induced by maturing DCs.
We repeated the immunogenicity experiments using more
criteria for T cell immunity, and we compared cytokine-
Figure 3. CD40 is required for the immunogenicity of DCs maturing in response to  -GalCer. (A) CD40    or wild-type B6 mice were primed with
2   107 OVA-loaded TAP    spleen cells plus i.v.  -GalCer 7 d later. Spleen cells were evaluated for the production of IFN-  in response to restimulation
by MHC class I (CD8  T)– or MHC class II (CD4  T)–binding OVA peptides. Insets indicate newly formed CD8  and CD4  T cells that produced
IFN-  upon OVA peptide reexposure. (B) As in A, except that the mean values for three experiments are shown. (C) Immunization of naive mice with
106 CD11c  DCs taken from wild-type or CD40    mice 4 h after administration of  -GalCer together with TAP    OVA-loaded splenocytes. Immunity
was monitored 7 d later by enumerating OVA-responsive CD4  and CD8  T cells as in A.Distinct Controls for Dendritic Cell Maturation In Vivo 1612
blocked and CD40    mice in parallel (Fig. 4). First, the
CD40    mice failed to prime for IL-2 and IFN- –producing
CD4  and CD8  T cells (Fig. 4 A, middle), whereas cytokine
blockade only had a partial inhibitory effect (Fig. 4 A, insets).
Second, the CD40    mice failed to prime for T cell prolifer-
ative responses in response to OVA restimulation, whereas
cytokine blockade had no inhibitory effect (Fig. 4 B; compare
arrows with asterisks). We used CFSE dilution to monitor T
cell proliferation because this is a more sensitive method than
[3H]thymidine uptake and is associated with little or no back-
ground (dilution of CFSE in the absence of antigen). Third,
CD40    mice failed to generate CD8  cytolytic effector cells
in vivo, whereas cytokine blockade did not detectably alter
killer activity relative to control mice (Fig. 4 C, arrows).
These results indicate that CD40 ligation is vital for initiating
several manifestations of T cell–mediated immunity.
CD40 Is Not Required for the Development of Signal One
and Signal Two on DCs Responding to  -GalCer In Vivo.
Because CD40 ligation increases MHC class I–peptide
complex formation in bone marrow derived DCs (23, 24),
we assessed if DCs in CD40    mice were able to present
OVA. To do this, CFSE-labeled, OVA-specific CD8  and
CD4  TCR transgenic T cells were injected separately. 18
h later, OVA-loaded dying splenocytes were injected i.v.
without or with  -GalCer. First, we verified the need for
bone marrow–derived cells in the presentation of cell-asso-
ciated protein because it has been reported that nonhe-
matopoietic, liver sinusoidal endothelial cells were also able
to present OVA on MHC class I by a TAP-dependent
pathway (39). However, using bone marrow chimeras, we
confirmed analogous experiments (40), finding that he-
matopoietic cells were essential for presentation of TAP   
Figure 4. Several forms of
CD4  and CD8  T cell priming
are blocked in mice lacking CD40,
but occur substantially during
blockade of TNF-  and IFN- 
(mouse groups defined in the top
row of labels). (A) As in Fig. 3 A,
mice were immunized with 2  
107 OVA-loaded TAP    spleen
cells and i.v.  -GalCer, and 7 d
later, antigen (OVA peptide)-
responsive, cytokine (IL-2 and
IFN- )-producing T cells were
monitored in spleen and ex-
pressed as a percentage of CD4 
(top) or CD8  (bottom) T cells
(insets). (B) As in A, but recall
proliferative responses (*) were
used to monitor T cell priming.
CFSE-labeled spleen cells from
the different groups of mice were
challenged during 3 d of culture
with 500  g/ml OVA protein.
(C) As in A, but the develop-
ment of cytolytic T cells was
monitored 7 d after immuniza-
tion. The groups of mice were
given a mixture of CFSE spleen
cells, 107 each loaded with
OVA257-264 peptide (high CFSE)
or not (low CFSE). 12 h later,
killing of antigen-loaded spleen
cells was detected (arrow) in
wild-type mice and in TNF   
mice treated with anti–IFN- 
antibody, but not in CD40   
mice. Data are representative of
three individual mice.Fujii et al. 1613
OVA splenocytes (Fig. S4, available at http://www.
jem.org/cgi/content/full/jem.20040317/DC1), presum-
ably DCs as described previously (8). When we com-
pared presentation of cell-associated OVA to TCR trans-
genic T cells transferred to wild-type and CD40    mice,
in the absence or presence of  -GalCer, the proliferation of
CD8  and CD4  T cells was identical, as indicated by
CFSE dilution and the increase in total T cell numbers in
the spleen (Fig. 5 A). Likewise, we found that CD40   
(Fig. 5 B) and CD40L    (Fig. S3 C) mice still up-regu-
lated CD80 and CD86 comparably to wild type upon chal-
lenge with  -GalCer. In addition, CD40    mice had sim-
ilar numbers of splenic DCs relative to wild type, with or
without stimulation by  -GalCer. These results indicate
that CD40 and CD40L are not required for splenic DCs to
present antigen and express CD80 and 86 costimulators;
Figure 5. CD40 ablation does not interfere with efficient DC expression of signal one (antigen presentation) and signal two (CD80/86 costimulation).
(A) Presentation of cell-associated OVA to OT-I, CD8 , and OT-II, CD4  TCR transgenic T cells in wild-type C57BL/6 or CD40    mice in the
absence or presence of  -GalCer. Total numbers of transgenic T cells (the mean of two experiments) are shown in each panel. (B) As in Fig. 1 E, 8 h
after i.v.  -GalCer to C57BL/6 or CD40    mice, the maturation of spleen CD11c  DC subsets was assessed at the level of three surface markers.
Table I. Cytokine Production Requirements for Dendritic Cells from Mice Given  -GalCer
Cytokine release from CD11c  splenic DCs
IFN-  TNF-  IL-12p40 IL-12p70
ng/ml pg/ml pg/ml pg/ml
C57BL/6, vehicle 0.7   0.4 119   9.6 693   71 0
 -GalCer treated
C57BL/6 23   0.8a 1,057   77a 2,338   124a 52   4.1a
TNF- /IFN-  block 4.0   1.0b 0 966   50b 0
CD40    13   1.4a 306   15b 1,074   174b 0
CD80/CD86    17   3.5a 679   1b 1,147   172b 27   12b
J 18    0.4   0.2 86   9c 772   103c 0c
2 h after giving mice vehicle or  -GalCer, CD11c  DCs were selected from the spleens and cultured for 24 h. Supernatants were analyzed by ELISA
for secretion of the indicated cytokines. Data are representative of four independent experiments. The p-value of the groups relative to the control
value was determined by a Student’s t test. 
aP   0.005.
bP   0.05.
cNo significant difference from C57BL/6 vehicle control (P   0.05).Distinct Controls for Dendritic Cell Maturation In Vivo 1614
i.e., signals one and two in the steady state and during acti-
vation with  -GalCer and NKT lymphocytes.
Inflammatory Cytokines and CD40 Ligation in Concert Lead
to IL-12 p70 Release.  We considered the possibility that
the need for CD40 in adaptive immunity reflected its role
in the production of IL-12 (41). In fact, IL-12p40 and p70
release from CD11c  splenic DCs was greatly reduced
when either inflammatory cytokines (TNF- , IFN- ) or
CD40 were nullified. In wild-type mice,  -GalCer in-
creased IL-12p40 threefold and induced the active IL-
12p70 heterodimer de novo, whereas the cytokine-blocked
and CD40    mice only increased IL-12p40 by 50% and
did not produce any IL-12p70 (Table I, compare second
with third and fourth rows). In contrast, substantial pro-
duction of cytokines including IL-12p70 took place in
CD80/86    mice. We also verified that NKT cells were
needed for  -GalCer to induce cytokine production by
DCs (Table I, compare second and bottom rows). We
tested if IL-12p40 contributed to immunity in response to
 -GalCer plus OVA. However, IL-12p40    mice were
fully competent to initiate immunity, both cytokine-pro-
ducing CD8  and CD4  effectors and cytolytic T cells
(Fig. S5, available at http://www.jem.org/cgi/content/
full/jem.20040317/DC1). Together, these data and the re-
sults in Fig. 2 indicate that some features of DC maturation
in response to  -GalCer are dependent on the production
of TNF-  and IFN-  (i.e., the up-regulation of costimula-
tory molecules [Fig. 1] and production of IL-12p70 [Table
I]), but neither leads directly to T cell–mediated immunity.
The Need for CD80 and CD86 Costimulatory Molecules.
Although our data showed that the marked CD80/86 up-
regulation during DC maturation did not initiate immunity
independently, we wanted to know if these costimulators
were required, perhaps at the lower but significant levels ob-
served on DCs in lymphoid tissues. Therefore, we extended
our studies to CD80/86    mice. Interestingly, DCs from
these mice, such as CD40    mice, could remodel their sur-
face in response to  -GalCer, as shown by the up-regulation
of the endocytic receptor DEC-205 (CD205) and down-
regulation of the IFN-  receptor (CD119; Fig. 6 A, gray).
Nevertheless, CD80/86    mice were unable to initiate an
immune response to  -GalCer and OVA (Fig. 6 B). There-
fore, the immunogenic properties of DCs maturing to
 -GalCer requires at least basal levels of CD80 and CD86.
Stimulation of the MLR by Maturing DCs Also Requires
Both Cytokines and CD40.  Another assay for the capacity
of maturing DCs to activate resting T cells is MLR stimula-
tion. Splenic DCs from  -GalCer–treated mice have greatly
increased MLR stimulatory activity (15). CD11c  DCs from
IFN-     mice were comparable MLR stimulators to those
from  -GalCer treated wild-type mice, whereas the DCs
from TNF-     mice were slightly less active (Fig. 7 A, left).
Because DCs could undergo additional maturation during
the MLR assay itself, we tested cells that were inhibited by
Figure 6. Requirement for CD80/86 for the adjuvant action of  -GalCer. (A) As in Fig. 1 E, 8 h after i.v. administration of  -GalCer to C57BL/6,
CD40   , or CD80/86    mice, the maturation of spleen CD11c  DC subsets was assessed at the level of surface markers using  -CD205 and  -CD119
antibodies. (B) As in Fig. 3, CD80/86    or wild-type B6 mice were primed with a combination of 2   107 OVA-loaded TAP    spleen cells and i.v.
 -GalCer. 7 d later, spleen cells were evaluated for the production of IFN-  in response to restimulation by MHC class I (CD8  T cells)– or MHC class
II (CD4  T cells)–binding OVA peptides. The results (insets) expressed as the percentage of CD4  or CD8  T cells producing IFN- , are representative
of four individual mice.Fujii et al. 1615
paraformaldehyde fixation immediately upon isolation. The
splenic CD11c  DCs from TNF-     mice now showed
less MLR stimulatory activity (P   0.05; Fig. 7 A, right).
When DCs were examined from TNF-     mice that also
received  -IFN-  antibody, there was no further reduction
in MLR stimulation in response to  -GalCer (unpublished
data). In contrast, when we tested DCs from mice injected
with TNF-  and/or IFN- , no MLR stimulation was ob-
served, in contrast with the strong MLR induced by DCs
from  -GalCer–treated mice (Fig. 7 B). This implied that
other factors, in addition to cytokines and CD80/86 up-reg-
ulation, were required for increased MLR stimulation by
DCs. Again, CD40 was playing a role because MLR stimu-
lation was reduced in its absence (Fig. 7 C). Therefore, the
induction of immunity by DCs, as assessed by stimulation of
the MLR, also requires cytokines and CD40 in concert.
Discussion
The  -GalCer Model for DC Maturation In Vivo.  -GalCer
was discovered to be an adjuvant for protective T cell im-
munity with an important antigen, irradiated malaria sporo-
zoites (19). The antigenic system we chose to study involved
a single intravenous injection of OVA-loaded dying spleno-
cytes (7, 8). These were rapidly captured (uptake was evident
within 30 min) and presented by a subset of CD8   splenic
DCs in vivo, the consequence of which is tolerance in the
steady state (8). We used OVA-loaded dying cells to model
the handling by DCs of dying cells from self tissues, tumors,
and infections. When given together with  -GalCer, uptake
of a single submicrogram dose of cell-associated OVA elicits
combined CD4  and CD8  T cell immunity (15, 16),
which is long lived and imparts resistance to OVA-trans-
duced tumors for at least 2 mo (unpublished data). To do
this,  -GalCer activates innate NKT lymphocytes that are
responsible for most of the major features of DC maturation,
such as remodeling of the DC surface to express high levels
of CD80 and CD86 costimulators and the production of nu-
merous cytokines (Table I and references 15, 16). These
consequences of innate NKT lymphocyte responses to
 -GalCer parallel what takes place with several microbial
ligands for toll-like receptors in vivo (4, 5, 42, 43).
Previous studies with ex vivo–derived and antigen-
loaded DCs showed that mature DCs were more immuno-
genic (32, 44). Likewise, immunity is induced in vivo by
administering antigen together with maturation stimuli
such as microbial products (5), infection (14), and agonistic
 -CD40 antibodies (9, 10, 17). Here, we have used the
 -GalCer/NKT model to begin to dissect the components
of maturation responsible for the induction of effective T
cell–mediated immunity. In contrast, much of the literature
on DC maturation from its very beginnings (45–48) has in-
volved surrogate criteria, especially a marked up-regulation
of costimulatory molecules and production of cytokines.
Figure 7. Cytokine and CD40
requirements for increased MLR
stimulatory activity. (A) 8 h after
i.v. administration of  -GalCer,
CD11c  DCs were used to stim-
ulate T cell proliferation (y axis)
in the MLR. Graded numbers of
spleen DCs from wild-type B6,
TNF-    , or IFN-     mice
were irradiated (30 Gy) and
added for 3 d in flat bottomed
96-well plates to 2   105 alloge-
neic BALB/c T cells (Allo MLR,
left) and C57BL/6 T cells (Syn
MLR, middle). To block DC
maturation in the T cell cocul-
ture, the DCs were fixed with
paraformaldehyde for 30 min and
irradiated followed by the addi-
tion to allogeneic T cells (right).
T cell proliferation was measured
by [3H]thymidine incorporation;
representative results of three in-
dependent experiments are shown.
(B) As in A, DCs from mice
given TNF-  and IFN-  i.v.
were fixed with paraformalde-
hyde for 30 min and irradiated
followed by the addition of allo-
geneic T cells, and [3H]thymi-
dine uptake was measured at
88–96 h. (C) As in A, DCs from
 -GalCer–treated wild-type and
CD40    mice were fixed, irra-
diated, and used to stimulate
the MLR.Distinct Controls for Dendritic Cell Maturation In Vivo 1616
Distinct Controls for the Components of DC Function during
Immunogenicity In Vivo.  There are several components to
the function of maturing DCs in initiating immunity, and
these proved to be under distinct controls in lymphoid or-
gans (Fig. S6, available at http://www.jem.org/cgi/content/
full/jem.20040317/DC1). Antigen presentation, or signal
one, occurred in the steady state, in the ostensible absence of
a maturation stimulus (Fig. 5). Interestingly, bone marrow–
derived DCs in culture showed greatly enhanced presenta-
tion on MHC class I as a result of CD40 ligation (23, 24).
Such up-regulation also might take place in vivo, but our
data indicate that DCs within lymphoid organs efficiently
formed MHC class I and II–peptide complexes in the steady
state (e.g., Fig. 5 A). We found previously that in the steady
state, the processing of dying cells resulted in tolerance in
vivo. Other studies in vitro concluded that DC maturation
(maturation being defined as cell surface remodeling with in-
creased expression of CD86) was required for deletional tol-
erance (49), although in our studies of cell-associated OVA
in vivo, such tolerance occurs in the steady state (8).
The production of many cytokines by splenic DCs did re-
quire the  -GalCer/NKT maturation stimulus. There was
strong and rapid production of IFN- , TNF- , and IL-
12p70 beginning within 2 h of glycolipid injection. We
found that these cytokines led to the major surrogate marker
for maturation, expression of high levels of CD80 and 86
costimulatory molecules (signal two) on most DCs. CD80
and 86 were clearly required for immunity to a coadminis-
tered antigen in the  -GalCer system (Fig. 6). In contrast,
NKT cell–dependent cytokine production by DCs occurred
to a substantial extent in CD80/86-deficient mice (Table I).
However, the greatly increased expression of costimulatory
molecules on maturing DCs did not independently link the
innate response between DCs and NKT cells to the adaptive
response, between DCs and   T cells; CD40 also was es-
sential. Likewise, when TNF-  was given to mice, or when
MLR stimulation was used to assess immune responses to
DCs (Figs. 2 and 7), we again observed that inflammation
and increased expression of CD80 and 86 did not lead inde-
pendently to immunity; CD40 ligation played a major role.
CD40L likely was provided by NKT cells early in the
DC–NKT interaction initiated by  -GalCer, but CD40L
might additionally contribute to the DC–T cell interaction
role when expressed by antigen-activated T cells. Interest-
ingly CD40L-bearing CD4  T cells were not essential for
the initiation of OVA-specific CD8  T cell immunity in our
model. Other potential sources of a CD40L signal for DCs
would include activated platelets, mast cells, and possibly,
heat shock proteins (50, 51). However, at this time, we have
not identified a means to selectively remove CD40L from
different types of cells, especially NKT cells and TCR   T
cells, to directly assess the relative importance of each source
of CD40L during the different stages of immunogenicity.
A valuable feature of the  -GalCer system was to be
able to dissect the consequences of different components
of DC maturation within a single system, and in vivo,
rather than by comparing different complex stimuli in
vitro, as previously was the case. The different stimuli for
DC maturation (inflammatory cytokines, CD40 ligands,
and microbial stimuli) each induce myriad distinct tran-
scriptional changes, so that it is hard to draw conclusions
concerning any one component by comparing cells stim-
ulated in different ways. By dissecting the controls of
DC maturation within a single system, we could observe
that efficient expression of MHC–peptide complexes and
CD86 costimulators did not lead to immunity in the ab-
sence of a CD40–CD40L interaction.
Roles for CD40–CD40L in DC Maturation.  The ef-
fects of CD40–CD40L in the  -GalCer system extend ear-
lier work on this TNF receptor family member. Previous
reports had concluded that agonistic  -CD40 antibodies
acted through DCs to bypass the need for CD4  helper
cells in CD8  T cell responses (27–29). The implication of
these and other studies (9, 10) was that CD40 was increas-
ing immunity by increasing formation of MHC–peptide
complexes and/or increasing expression of costimulatory
molecules, either membrane bound like CD80 and CD86,
or soluble cytokines including IL-12. The formation of
these T cell costimulatory molecules is a well known fea-
ture of DCs maturing in response to CD40 ligation (21, 22,
25, 26). CD40 also influences DC survival (52), migration
(53), and avoidance of suppression (54, 55). The surprise in
the current work was the major dependence of both CD4 
and CD8  T cell responses on CD40 expression by DCs,
under circumstances when active CD40-independent anti-
gen presentation and costimulation were already in place.
Identification of the CD40-based changes in DCs should
contribute to further understanding of DC function and
immunogenicity mechanisms.
A distinctive role for CD40 was envisaged by other stud-
ies in which CD40-ligated, bone marrow–derived DCs
proved to be better inducers of T cell responses than DCs
matured by other stimuli in culture (56, 57). Our results
show that CD40 ablation in vivo does not retard antigen
presentation and the expression of high levels of costimula-
tors by DCs in lymphoid tissues. Yet CD40 still has a major
role in linking innate to adaptive immunity and for both
CD4  and CD8  T cell responses. These observations sug-
gest changes in the standard signal one–signal two theory as
a sufficient mechanism used by DCs to link innate with
adaptive immunity.
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